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Background. Hox genes are implicated in hematopoietic stem cell (HSC) regulation as well as in leukemia development
through translocation with the nucleoporin gene NUP98. Interestingly, an engineered NUP98-HOXA10 (NA10) fusion can
induce a several hundred-fold expansion of HSCs in vitro and NA10 and the AML-associated fusion gene NUP98-HOXD13
(ND13) have a virtually indistinguishable ability to transform myeloid progenitor cells in vitro and to induce leukemia in
collaboration with MEIS1 in vivo. Methodology/Principal Findings. These findings provided a potentially powerful approach
to identify key pathways mediating Hox-induced expansion and transformation of HSCs by identifying gene expression
changes commonly induced by ND13 and NA10 but not by a NUP98-Hox fusion with a non-DNA binding homedomain
mutation (N51S). The gene expression repertoire of purified murine bone marrow Sca-1+Lin- cells transduced with retroviral
vectors encoding for these genes was established using the Affymetrix GeneChip MOE430A. Approximately seventy genes
were differentially expressed in ND13 and NA10 cells that were significantly changed by both compared to the ND13(N51S)
mutant. Intriguingly, several of these potential Hox target genes have been implicated in HSC expansion and self-renewal,
including the tyrosine kinase receptor Flt3, the prion protein, Prnp, hepatic leukemia factor, Hlf and Jagged-2, Jag2. Consistent
with these results, FLT3, HLF and JAG2 expression correlated with HOX A cluster gene expression in human leukemia samples.
Conclusions. In conclusion this study has identified several novel Hox downstream target genes and provides important new
leads to key regulators of the expansion and transformation of hematopoietic stem cells by Hox.
Citation: Palmqvist L, Pineault N, Wasslavik C, Humphries RK (2007) Candidate Genes for Expansion and Transformation of Hematopoietic Stem Cells
by NUP98-HOX Fusion Genes. PLoS ONE 2(8): e768. doi:10.1371/journal.pone.0000768
INTRODUCTION
The 39 clustered Hox proteins are an evolutionary preserved
family characterized by a 60 amino acid DNA-binding motif
called the homeodomain. Hox genes of the A, B and C but not D
clusters are transcribed during normal hematopoiesis with their
expression being confined to the immature subpopulations.
Elimination or enforced expression of certain clustered Hox genes
in mouse models has demonstrated profound effects on hemato-
poietic differentiation and persistent expression of normal or
mutated Hox proteins in hematopoietic progenitors can result in
leukemia in both mice and humans [1,2]. Hox genes have also
been linked to leukemia by virtue of their involvement in
leukemia-specific translocations. Clustered Hox genes have re-
peatedly been identified in acute myeloid leukemia (AML)
harboring translocations that generate novel fusion proteins
containing the N terminal region of the nucleoporin gene,
NUP98, and the C terminal Hox region including the home-
odomain (HD). The involvement of homeobox genes as partners
of NUP98 is of particular interest given the growing evidence
linking Hox genes, particularly members of the 59-located members
of the HOXA cluster, such as HOXA9, to leukemia. To date at
least seven clustered Hox genes have been found fused to NUP98
in human leukemia, interestingly only from the Abd-B clustered
Hox [3–11]. Furthermore, two non-clustered homeodomain-
containing genes PMX1 and PMX2 have also been identified as
NUP98 fusion partners in de novo AML and t-AML respectively
[12,13].
The mechanisms by which Hox proteins mediate their effects
and how they perturb cellular functions are not well understood.
They seem to be highly context dependent in their actions [14]
and in normal hematopoiesis their expression is tightly regulated
[15]. Expression analysis and gain- or loss- of function studies have
shown that Hox proteins play an important role in the regulation
of early stages of hematopoiesis, including the self-renewal of
hematopoietic stem cells and early progenitors [16]. DNA site-
selection studies indicate that the homeodomain by itself has
limited target sequence recognition. Additional binding specificity
and stability is in part achieved through interaction with other
homeodomain-containing proteins from the multimember PBX or
MEIS1 families [17] and co-transduction of MEIS1 with Hox and
NUP98-Hox genes also strongly accelerate the onset of leukemia in
mice [18–20]. There is also a considerable redundancy between
different NUP98-Hox fusions in effects when expressed in bone
marrow cells in vitro and their ability to collaborate with MEIS1 in
vivo. An engineered NUP98-HOXA10 (NA10) fusion and the
AML-associated fusion gene NUP98-HOXD13 (ND13) have
a virtually indistinguishable ability to transform myeloid pro-
genitor cells in vitro and to induce leukemia in collaboration with
MEIS1 in vivo [21]. Furthermore, it has been shown that a N51S
mutation in the DNA binding homeodomain abolishes the DNA
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associated fusion gene NUP98-HOXD13 (ND13) fusion also loses
its leukemic effect from this mutation [19].
The relatively long latency of Hox-induced AML in mouse
models strongly indicates that additional genetic events are
required for full leukemic progression [19,23,24]. Indeed, data
supports that Hox-containing fusions, as for most transcription
factor-containing fusion oncogenes, alter the growth and differen-
tiation of early hematopoietic precursors leading to the establish-
ment of a preleukemic population of cells that are then susceptible
to the acquisition of cooperating mutations [25]. In concordance
with such a model, we recently demonstrated that constitutive
expression of ND13 or NA10 was sufficient to induce a pre-
leukemic state in primary bone marrow (BM) cells after extended
in vitro culture. Though these cells had short-term repopulating
potential, they were for the most part incapable of inducing AML
on their own but could readily be converted into AML-inducing
cells when complemented with MEIS1 or other genes [26].
Intriguingly, in short term culture, NA10 can promote high level
expansion of long term repopulating cells; moreover a NUP98-
fusion restricted to the homeodomain of HOXA10 induces similar
levels of expansion of HSC [27]. Together, these findings suggest
that NUP98-Hox fusions genes impact on crucial genetic
programs involved in stem cell self-renewal and proliferation that
may also contribute to leukemic transformation.
In an effort to gain insight into the nature of the possible genetic
programs impacted by Hox relevant to stem cell self-renewal and
leukemogenesis we have used microarray technology to assess gene
expression perturbations induced by NUP98-HOX fusions
24 hours post transduction into murine primary bone marrow
Sca-1+Lin- cells enriched in HSC and progenitors cells. We
compared two NUP98-HOX fusions (NA10 and ND13) with a non
DNA-binding and non-transforming ND13(N51S) homeodomain
mutant. Surprisingly, a relatively small number of genes were
significantly differentially expressed in cells harboring the ND13 or
NA10 fusions compared to control cells and several potential
target genes implicated in HSC expansion and self-renewal were
identified with this approach.
MATERIALS AND METHODS
cDNA constructs and retroviral vectors
The NUP98-HOXA10 and NUP98-HOXD13 fusion gene as well
as the N51S-ND13 dead homeodomain mutant gene constructs
have been described elsewhere [19]. In short, the cDNAs were
subcloned into the murine stem-cell virus (MSCV) 2.1 vector
upstream of the internal ribosomal entry site (IRES) sequence
linked to the gene encoding the enhanced green fluorescence
protein (EGFP; Clontech). As a control, the MSCV vector
carrying only the IRES-GFP cassette (GFP virus) was used.
Production of high-titer, helper-free retrovirus was carried out by
standard procedures [28]. Constructs have been validated by
sequencing and correct expression and transmission were
confirmed by western blot and Southern blot analysis.
Retroviral infection of primary bone marrow cells
Mice were bred and maintained at the British Columbia Cancer
Research Centre animal facility. Donors of primary BM cells were
older than 12-weeks (C57Bl/6Ly-Pep3b6C3H/HeJ) F1 (PepC3)
mice. Primary mouse BM cells were transduced as previously
described [29]. Briefly, BM cells were harvested from mice treated
4 days previously with 150 mg/kg 5-fluorouracil (Faulding,
Underdaler, Australia) and prestimulated for 48 hours in
Dulbecco modified Eagle medium (DMEM) supplemented with
15% fetal bovine serum (FBS), 10 ng/mL human interleukin-6
(hIL-6), 6 ng/mL murine interleukin-3 (IL-3), and 100 ng/mL
murine stem cell factor (mSF) (StemCell Technologies, Vancou-
ver, BC, Canada). Cells were infected by co-cultivation with
irradiated (4000 cGy x-ray) GP+E86 viral producer cells with the
addition of 5 mg/mL protamine sulfate (Sigma, Oakville, ON,
Canada). Loosely adherent and nonadherent cells were harvested
from the co-cultures after 2 days and were cultured for 24 hours in
the same medium without protamine sulfate.
Cell sorting and harvest
The single cell suspensions collected were blocked for 10 min on
ice with 5 mg/ml anti mouse CD16/CD32 (Fc Block, BD
Pharmingen) in Phosphate Buffered Saline (STI)+2% Fetal Bovine
Serum (PF). Cells were washed once with PF and then incubated
on ice for 20 min with the primary mAb. Cells were then washed
once, incubated with the secondary antibody if needed, washed
again, and then analysed by flow cytometry using a FACSCali-
bur
TM flow cytometer and CELLQuest
TM software (BD Pharmin-
gen). GFP+ Sca-1+Lin- cells were sorted using a FACSVantage
TM
(BD Pharmingen). Purity.90% were confirmed by re-analysis of
sorted cells. The forward versus side scatter profile was used to
gate on viable cells and an unstained sample was used to
determine appropriate gating for expression. Monoclonal anti-
bodies (mAbs) were all purchased from PharMingen (San Diego,
CA) (phycoerythrin [PE]–labeled Gr-1, B220, Ter-119, CD4,
CD5 and CD8).
RNA extraction and array hybridization
Sorted cells were lyzed in Trizol
TM (Invitrogen) and total RNA
was extracted according to the manufacturer instructions. One
hundred ng of total RNA from each sample were then double linear
amplified with the ENZO BioArray High Yield RNA Transcript
Labeling kit and the GeneChip Eukaryotic Small Sample Target
Labeling Assay, Version II protocol (Affymetrix, Santa Clara, CA) to
produce target for hybridization to Affymetrix MOE430 according
to the manufacturer’s instructions and performed at the Genome
Science Centre, BC Cancer Agency, Vancouver, Canada. All
experiments were performed in biological triplicate.
Gene array analysis
Gene array data (CEL-files) were imported into GeneSpringH
software version 7.3 (Silicon Genetics, Redwood City, CA). The
GC-RMA method [30] was used for normalization and data was
processed as follows: all values below 0.01 were set to 0.01, all of
the genes in each sample were divided by the median of the
specified list of 100 positive control genes present on the MOE430
chip and all samples were then normalized against the median of
the MIG control samples. Each measurement for each gene in
those specific samples was divided by the median of that gene’s
measurements in the corresponding control samples. We judged
genes to be differentially expressed when the difference in
expression in the ND13 and NA10 condition vs. the GFP control
or the non-leukemic ND13(N51S) condition was at least 50%; and
the extent of difference in expression was significantly different in
the Student’s t-test (p,0.05). Classification of genes into functional
categories and to analyze signaling pathways was done by
collecting annotations and keywords with the Onto-Express
software [31] (http://vortex.cs.wayne.edu/ontoexpress), Affymtrix
NetAffx (http://www.affymetrix.com/analysis/index.affx) and the
Gene Ontology Tool and KEGG maps included in the Gene-
Spring 7.3 Software. Unigene and RefSeq IDs were used in the
analysis to exclude redundant genes included in the array probe
NUP98-HOX Fusion Target Genes
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(GEO), (http://www.ncbi.nlm.nih.gov/geo) and the MIAME
(minimal information about a microarray experiment) guidelines
was followed for data presentation.
Quantitative RT-PCR validation of murine bone
marrow cells
Non-amplified RNA from the transduced murine primary bone
marrow samples was used for validation with quantitative RT-PCR
(qRT-PCR). RNA was isolated using Trizol
TM and the samples were
then treated with DNase I (amplification grade, Invitrogen).
Complementary DNA (cDNA) was generated by reverse transcrip-
tion (RT) with the iScript cDNA Synthesis Kit (BioRad Inc.,
Hercules, CA). Gene transcripts were quantified by real-time PCR
using the iCycler apparatus (Bio-Rad Inc., Hercules, CA) and were
detected with SYBR Green as flurochrome (IQ
TM SYBRH Green
Supermix, BioRad Inc.). Gene sequences for primer design were
obtained from the NCBI Reference Sequences database (http://
www.ncbi.nlm.nih.gov/RefSeq/). Primers were chosen using the
Primer3 software (http://www.broad.mit.edu/cgi-bin/primer/
primer3_www.cgi) and the specificity of all primer pairs was tested
with electronic PCR using the mouse genome and the mouse
transcript database (http://www.ncbi.nlm.nih.gov/sutils/e-pcr/
reverse.cgi). The relative expression changes were determined with
the 2
2DDCT method [32] and the housekeeping glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene transcript was used to
normalize the results. Primer sequences (59 to 39); Pbx1(NM_008783)
forward primer ATCGGGGACATTTTACAGCA and reverse
primer AGGCTTCATTCTGTGGCAGT; Pbx2 (NM_017463)
TGAAGCAAAGCACCTGTGAG and AGTGGCCTGTTTGC-
TGAAGT; Pbx3 (NM_016768) AGAGCCAAATTGACCCAGAT
and ATGGGACGCGTTCTACTCTG; HoxA5 (NM_010453)
CGCAAGCTGCACATTAGTCA and AGGTAGCGGTTGAA-
GTGGAA; HoxA7 (NM_010455) GAAGCCAGTTTCCGCATC-
TA and CGTCAGGTAGCGGTTGAAAT; HoxA9 (NM_010456)
ACAATGCCGAGAATGAGAGC and GTTCCAGCGTCTGG-
TGTTTT; HoxB4 (NM_010459) CTGGATGCGCAAAGTTCAC
and TCCTTCTCCAACTCCAGGAC; Meis1 (NM_010789) GCA-
CAGGTGACGATGATGAC and AGGGTGTGTTAGATGCT-
GGAA, Meis2 (NM_010825) AACGACGCCTTGAAAAGA-
GA and GCTCGCACTTCTCAAAAACC; Meis3 (NM_008627)
CAGCGACAGCTTGAAGAGAG and GCCAGCTCACACTT-
CTCAAA; Flt3 (NM_010229) ATCCTTCCCCAACCTGACTT
and TTGCCACCCATGTTCTGATA; Evi1 (NM_007963) GGA-
GGAGGACTTGCAACAAA and GACAGCATGTGCTTCTC-
CAA; Anxa1 (NM_010730) CACAGAGCCACCAGGATTTT and
CGTTCGGAAATTGACATGAA; Tgfbi (NM_009369) GGAAG-
CTTCACCATCTTTGC and ATGTTGACGTTGCTCACCAG;
c-Jun (NM_010591) TCCCCTATCGACATGGAGTC and
TTTTGCGCTTTCAAGGTTTT; Csf2rb (NM_007781) CCTG-
GAACAAGGGAAGTTCA and CAATGCAGGCTGTAGCTG-
TC; Ptprf (NM_011213) TGGCCATCTCTTCATTAGGC and
ACAGGCTCGGTATTTCCAGA; Gapdh (NM_008084) AACT-
TTGGCATTGTGGAAGG and ATGCAGGGATGATGTTC-
TGG.
Patient samples
The part of the study involving patient samples and healthy
volunteers was performed in accordance to the Declaration of
Helsinki and with approval by the local ethics committee at
Go ¨teborg University and informed written consent was obtained
from all participants. All samples were collected at diagnosis
between year 2000 and 2006 and stored at the department of
Clinical Chemistry and Transfusion Medicine at Sahlgrenska
University Hospital. The analysis included 34 adult patients, 20
females and 14 males, with de novo AML, representing FAB
subclasses M0-M5. Mean age at diagnosis was 56 year (range 26
to 83). Four healthy volunteers were donors of normal bone
marrow that was pooled for assay normalization.
TaqManH Low density array (TLDA)
RNA from patient and healthy volunteer samples was isolated using
Trizol
TM (Invitrogen, Cat.No. 15596-026). Complementary DNA
(cDNA) was generated from 500 ng RNA by reverse transcription
(RT) with random primers and the Superscript II enzyme and
RNase inhibitor (Invitrogen) ina reaction volume of 20 mL. The RT
reaction was incubated at 42uC for 50 minutes followed by
15 minutes at 70uC. Before the enzymes were added the mix was
preheated at 65uC for 10 minutes. All assays were performed on an
ABI Prism 7900 HT real-time PCR-system with ABI SDS Software
2.2.3 (Applied Biosystems, Foster City, CA, USA). For the TLDA
20 mL of cDNA, corresponding to 25 ng starting RNA, was mixed
with 30 mLw a t e ra n d5 0mL TaqMan Universal PCR Master Mix
(Applied Biosystems, Stockholm, Sweden); 100 mL was loaded per
port. Thermal cycling conditions were 50uC for 2 minutes, 94.5uC
for 10 minutes, 97uC for 30 seconds and 59.7uC for 1 minute. The
relative expression changes were determined with the 2
2DDCT
method [32] and the housekeeping beta-glucuronidase (GUSB,
Hs99999908_m1) gene transcript was used to normalize the results.
The following genes were analyzed (TaqMan assay ID number
is indicated, Applied Biosystems); HOXA5 (Hs00430330_m1),
HOXA7 (Hs00600844_m1), HOXA9 (Hs00365956_m1),
HOXA10 (Hs00538183_m1), PBX1 (Hs00231228_m1), PBX2
(Hs00855025_s1), PBX3 (Hs00608415_m1), MEIS1
(Hs00180020_m1), MEF2C (Hs00231149_m1), JAG2
(Hs00171432_m1), PRNP (Hs00175591_m1), DDX4
(Hs00251859_m1) and HLF (Hs00171406_m1).
Statistical analysis
Microsoft
H Excel in combination with the Excel plug-in software
Analyse-It
H v1.73 was used for the statistical calculations. Pearson
regression was used for comparison between gene array and qRT-
PCR results. Spearman rank correlation was used to test possible
associations. Non-parametric Kruskal-Wallis 1-way ANOVA were
used to evaluate differences between groups.
RESULTS
Transduction of murine primary bone marrow
Adult murine bone marrow cells transduced with vectors carrying
ND13, NA10, ND13(N51S) or an empty GFP control vector were
isolated on the basis of GFP expression by FACS 24 hours post-
transduction. Viable transduced cells were further enriched for
primitive hematopoietic cells by exclusion of cells expressing linage
markers (Gr-1, B220, Ter-119, CD4, CD5 and CD8) and selection
for cells expressing the stem cell antigen-1 (Sca-1). This resulted in
an overall recovery of 0.25–6% of all cells with a purity of 90–95%
for GFP expression. The cells were kept on ice during sorting and
immediately lyzed in Trizol for RNA extraction. Three in-
dependent experiments were performed for each of the four
different conditions included in the study.
Gene array analysis and validation
After extraction, RNA was amplified and analyzed using the
Affymetrix GeneChip MOE430A array containing 23,000 probe
sets. The Gene Chip robust multi-array analysis (GC-RMA) was
NUP98-HOX Fusion Target Genes
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per gene normalization. Pearson correlation coefficient between
the experimental replicates ranged between r=0.92–0.99 suggest-
ing low inter-experimental variation and the 39-to-59 ratios for
Gapdh and Actin in all samples were less than 3.0 (ranging from
1.7–2.7), indicating that no serious bias was introduced by the
RNA amplification procedure. Our main interest was to define the
subset of genes that could explain the transforming and cell
expansion potential of NUP98-HOX fusions in the Sca-1+, GFP+,
Lin- cell population and that also could be direct NUP98-Hox
binding target genes. First, all genes that were significantly
differentially expressed between ND13, NA10 or the presumably
non DNA-binding ND13(N51S) and the GFP control were
identified. Genes were considered differentially expressed if they
had a change in expression level compared to control of at least
50% and the extent of difference in expression was statistically
significant (p,0.05) in a parametric Welsh-ANOVA t-test. More
genes were activated than repressed by all NUP98-HOX fusions,
560 activated and 43 repressed genes with ND13, 414 activated
and 20 repressed genes with NA10 and 204 activated and 82
repressed genes with ND13(N51S), (Figure 1). ND13 and NA10
had relatively more activation compared to the ND13(N51S)
mutant and there was only a significant overlap on activated genes
between ND13 and NA10 (Figure 1). Furthermore, of the 170
differentially expressed genes that were induced by both ND13
and NA10, 74 of these genes also differed significantly between
ND13 and NA10 and the functionally inert ND13(N51S) mutant
genes with at least a 50% difference in expression level (Table 1).
These results suggest that ND13 and NA10 mainly act as
transcriptional activators in undifferentiated BM cells and that
this effect is dependent on an intact homeodomain. Moreover, the
gene array results also indicate that a relatively small number of
activated genes can be linked to NUP98-Hox induced effects on
primitive hematopoietic cell function.
To confirm the fidelity of the microarray data a subset of 15
genes was selected for validation using quantitative RT-PCR
(Table 2). Quantitative real-time RT-PCR was used to measure
relative abundances. The housekeeping gene GAPDH was used as
an endogenous control to normalize the data. The fold change was
calculated between the GFP control and the NA10, ND13 and
ND13(N51S) samples respectively. The majority of the individual
fold changes determined from the gene array was verified by qRT-
PCR (Table 2). Overall the analysis revealed a good correlation
between the gene array data and the qRT-PCR results (Pearson
correlation, r=0.83), with a tendency that the PCR results showed
greater changes than what the array suggested. Taken together the
validation analysis provides confidence in our approach to identify
differentially expressed genes with a high likelihood of exhibiting
true expression level changes.
Functional classification and analysis of
differentially expressed genes
The 74 genes that were both induced by ND13 and NA10 and
whose expression was dependent on an intact homedomain were
classified into gene ontology categories according to involvement
in different biological processes. The genes were separated into 12
main categories (Figure 2). A relatively high number of
differentially expressed genes were classified as being involved in
development and differentiation (16 genes), cell cycle, cell growth
and/or cell proliferation (13 genes) or signal transduction (19
genes). At least 16 genes were classified as being involved in
transcriptional regulation (Table 1). Thus, processes potentially
important for cell self-renewal, expansion and transformation.
Several of the genes induced by ND13 and NA10 were Hox or
Hox cofactors (Hoxa5, Hoxa7, Hoxa9 and Pbx3, Table 1). No
significant change of gene expression could be seen for Pbx1, Pbx2
or Meis1, also verified with Q-RT-PCR (Table 2), but all three
genes were expressed in the Sca1+, Lin- BM cell population in
concordance with published results [33]. Meis2 and Meis3 could
not be detected either by gene array or Q-RT-PCR (data not
shown). These findings are basically in line what have been
reported in other studies [34–36]. Besides the Hox or Hox co-
factors several other putative target genes of ND13 and NA10 are
involved in cell development and proliferation. This included
induction of the DEAD-box protein gene Ddx4, the hepatic
leukemia factor (Hlf), the MADS box transcription enhancer factor
2C (Mef2c), the prion protein gene (Prnp) and Jagged-2 (Jag2). The
Drosophila ortholog of Ddx4, VASA, has a central role in germ cell
development and is conserved in invertebrates and vertebrates.
Ddx4 is a member of the DEAD box family of ATP-dependent
RNA helicases, the same gene family as Ddx10 belongs to, which
has been found in translocations with NUP98 [37]. The prion
protein has been shown to be present on human CD34+ bone
marrow (BM) stem cells [38] and was recently shown to be
expressed on long-term hematopoietic stem cells and to be
important in hematopoietic stem cell self-renewal [39]. The HLF
gene has been found in translocations together with E2A in human
acute lymphoblastic leukemia [40] and enforced HLF expression
has been reported to enhance both HSC engraftment and to
inhibit apoptosis [41]. The MEF2 family of regulatory proteins are
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Figure 1. Venn diagram of genes significantly activated (A) or
repressed (B) in Sca1+, Lin- BM cells expressing the ND13, NA10 or
ND13(N51S) mutant fusion genes compared to GFP control.
doi:10.1371/journal.pone.0000768.g001
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..................................................................................................................................................
Gene name and description Accession #
ND13 fold
change
ANOVA
p-value
NA10 fold
change
ANOVA
p-value Biological process
Crisp1, cysteine-rich secretory protein 1 NM_009638 18.3 6.04E-06 30.8 7.92E-06 Unknown
Nr4a1, nuclear receptor subfamily 4, group A,
member 1
NM_010444 8.1 2.90E-02 1.8 5.70E-03 Transcription
Igh-6, immunoglobulin heavy chain 6 (heavy
chain of IgM)
BB226392 5.0 2.90E-03 3.2 3.81E-05 Signal transduction/Immune
response/Cell proliferation
Ptprf, protein tyrosine phosphatase, receptor
type, F
BF235516 4.5 3.69E-03 1.8 1.10E-03 Signal transduction
Pdcd1lg2, programmed cell death 1 ligand 2 NM_021396 4.1 3.79E-05 2.0 2.42E-03 Cell proliferation
Pbx3, pre B-cell leukemia transcription factor 3 NM_016768 3.9 6.23E-06 4.8 1.19E-05 Transcription/Development
Hlf, hepatic leukemia factor NM_172563 3.4 3.52E-02 6.8 4.03E-04 Transcription/Cell proliferation
Ahr, aryl-hydrocarbon receptor NM_013464 3.4 2.54E-03 3.1 2.35E-05 Transcription/Signal transduction
Hlx1, H2.0-like homeo box 1 NM_008250 3.4 3.99E-03 1.8 4.96E-03 Transcription
Ier3, immediate early response 3 NM_133662 3.3 9.35E-04 1.5 8.00E-03 Unknown
Erbb2ip, Erbb2 interacting protein BM240030 3.3 9.17E-04 2.3 1.21E-03 Signal transduction
Tmem71, transmembrane protein 71 AV173260 3.0 4.03E-05 2.5 4.65E-05 Unknown
Pkp2, plakophilin 2 AA516617 3.0 7.13E-06 1.7 1.48E-03 Cell adhesion/Development
Pira1, paired-Ig-like receptor A1 NM_011093 3.0 1.56E-02 2.3 2.13E-02 Cell cycle/Immune response
Tgm2, transglutaminase 2, C polypeptide BB041811 2.9 2.99E-03 2.9 3.04E-03 Signal transduction/Metabolism/Cell
adhesion
Lilrb3, leukocyte immunoglobulin-like receptor,
subfamily B, member 3
U96693 2.8 5.50E-03 2.0 8.22E-04 Cell cycle/Immune response
Cables1, Cdk5 and Abl enzyme substrate 1 AF328140 2.8 2.87E-03 1.8 2.59E-02 Cell cycle/Development
H2-DMa, histocompatibility 2, class II, locus DMa NM_010386 2.8 7.61E-03 2.2 1.74E-02 Immune response/Transport
Ahrr, aryl-hydrocarbon receptor repressor NM_009644 2.7 9.31E-04 2.2 2.48E-03 Signal transduction/Transcription/
Metabolism
Fads3, fatty acid desaturase 3 BE652876 2.7 1.07E-02 1.9 7.20E-03 Metabolism
Tspan6, tetraspanin 6 NM_019656 2.7 1.14E-04 1.7 2.10E-03 Unknown
Tmem51, transmembrane protein 51 BC003277 2.7 5.61E-03 2.1 3.87E-03 Unknown
Rab4a, RAB4A, member RAS oncogene family NM_009003 2.6 1.41E-03 3.4 1.40E-04 Transport/Signal transduction
Anxa1, annexin A1 NM_010730 2.5 3.65E-03 2.4 4.42E-03 Cell cycle/Cell proliferation/Signal
transduction
Pscdbp, pleckstrin homology, Sec7 and coiled-
coil domains, binding protein
BC007144 2.4 3.04E-03 1.6 4.34E-02 Cell adhesion
F2rl2, coagulation factor II (thrombin) receptor-
like 2
NM_010170 2.4 8.34E-04 2.2 9.01E-04 Coagulation/Signal transduction
RIKEN cDNA C230093N12 gene BC023470 2.4 2.04E-03 1.5 1.70E-02 Unknown
Cish, cytokine inducible SH2-containing protein NM_009895 2.4 6.78E-04 1.6 3.19E-02 Cell growth/Signal transduction
Tsc22d1, TSC22 domain family, member 1 BB357514 2.4 2.60E-03 2.0 7.37E-03 Transcription
Wdfy2, WD repeat and FYVE domain containing 2 BB794924 2.4 6.33E-03 1.7 6.51E-03 Unknown
Pld3, phospholipase D family, member 3 NM_011116 2.3 8.47E-03 2.6 4.39E-05 Metabolism
Dnase1l1, deoxyribonuclease 1-like 1 AK009174 2.3 1.84E-02 1.9 2.87E-02 Metabolism
Mylc2pl, myosin light chain 2, precursor
lymphocyte-specific
NM_021611 2.3 2.35E-02 2.9 1.82E-03 Unknown
RIKEN cDNA 1700027N10 gene BC019423 2.3 4.46E-04 2.2 8.76E-04 Unknown
Cyp4f16, cytochrome P450, family 4, subfamily f,
polypeptide 16
NM_024442 2.3 5.32E-04 1.9 2.91E-03 Transport
Hoxa5, homeo box A5 BC011063 2.3 7.95E-04 3.9 3.02E-05 Transcription/Development
Crisp3, cysteine-rich secretory protein 3 NM_009639 2.2 1.20E-04 2.1 3.50E-02 Unknown
Procr, protein C receptor, endothelial NM_011171 2.2 8.99E-03 2.5 5.25E-05 Coagulation
Plek, pleckstrin AF181829 2.2 5.53E-03 1.8 1.44E-02 Signal transduction
Mitf, microphthalmia-associated transcription
factor
BB763517 2.2 9.81E-03 1.9 2.58E-03 Development/Transcription
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PLoS ONE | www.plosone.org 5 August 2007 | Issue 8 | e768involved in myogenesis and the Mef2c gene is important for normal
morphogenesis [42]. Jagged-2 (Jag2) is a ligand that activates
NOTCH1 and related receptors that are critical for various cell
fate decisions. Furthermore, the tyrosine kinase receptor Flt3 was
found to be induced by ND13 and NA10 in Sca1+, Lin- primary
BM cells. We and others have previously shown that Flt3
expression is induced by Meis1 in a context with either high
expression of NUP98-Hox fusions [43] or HOXA9 [44] and the
present finding further strengthen the conclusion that the Flt3 is
a direct target gene of Hox and Hox co-factors in primary HSCs
or progenitor cells.
Correlation of gene expression in human AML
To discern what target genes identified in the microarray analysis
might be involved in leukemic transformation and to investigate if
they are associated with Hox and Hox co-factor expression, 34 de
Gene name and description Accession #
ND13 fold
change
ANOVA
p-value
NA10 fold
change
ANOVA
p-value Biological process
Metrnl, meteorin, glial cell differentiation
regulator-like
BC024445 2.1 2.00E-02 2.2 1.79E-02 Unknown
Prnp, prion protein BE630020 2.1 2.13E-03 2.3 8.29E-03 Metabolism
Sord, sorbitol dehydrogenase AV253518 2.1 1.49E-02 2.3 5.31E-04 Unknown
Rpgrip1, retinitis pigmentosa GTPase regulator
interacting protein 1
AK015037 2.1 1.98E-04 1.6 3.35E-03 Development
Gsn, gelsolin NM_010354 2.1 8.22E-03 2.1 2.22E-02 Transport
Hoxa7, homeo box A7 NM_010455 2.0 2.45E-02 1.7 2.38E-02 Transcription/Development
Mef2c, myocyte enhancer factor 2C AI595932 2.0 2.58E-02 1.7 6.06E-03 Transcription/Development
Eltd1, EGF, latrophilin seven transmembrane
domain containing 1
BC017134 2.0 2.94E-04 1.9 4.89E-04 Signal transduction
Flt3, FMS-like tyrosine kinase 3 NM_010229 2.0 2.44E-02 2.0 2.32E-02 Signal transduction/Development
Ncoa1, nuclear receptor coactivator 1 NM_010881 1.9 2.24E-02 1.5 6.81E-03 Transcription/Signal transduction
Ddx4, DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 AK014844 1.9 2.04E-03 13.3 1.92E-06 Development
Calcrl, calcitonin receptor-like AF209905 1.9 1.37E-02 1.8 1.97E-02 Cell proliferation/Signal
transduction/Development
St8sia4, ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 4
NM_009183 1.9 1.87E-03 2.0 1.77E-03 Metabolism
Glul, glutamate-ammonia ligase AI391218 1.9 1.09E-02 1.7 1.64E-02 Metabolism
Lrp10, low-density lipoprotein receptor-related
protein 10
BC011058 1.9 3.27E-03 1.8 5.96E-03 Metabolism/Transport
Hoxa9, homeo box A9 NM_010456 1.8 1.06E-02 2.5 1.33E-03 Transcription/Development
Malat1, metastasis associated lung adenocar-
cinoma transcript 1
AW012617 1.8 3.31E-02 1.9 1.27E-03 Unknown
Ptk2b, PTK2 protein tyrosine kinase 2 beta AV026976 1.8 8.99E-03 1.7 1.34E-02 Signal transduction
Igfbp7, insulin-like growth factor binding protein 7 AI481026 1.8 1.25E-02 1.7 2.41E-02 Cell growth/Metabolism
Mxd4, Max dimerization protein 4 BG868949 1.8 1.23E-02 1.8 7.84E-03 Transcription
Sesn1, sestrin 1 BG076140 1.8 1.60E-03 1.8 1.42E-03 Cell cycle
Itm2c, integral membrane protein 2C NM_022417 1.8 3.67E-03 1.5 2.97E-02 Unknown
RIKEN cDNA 4930504E06 gene BB010153 1.7 2.71E-02 1.8 2.82E-03 Unknown
Man1a, mannosidase 1, alpha NM_008548 1.7 9.38E-03 1.6 1.53E-02 Metabolism
Aldoc, aldolase 3, C isoform BC008184 1.7 2.36E-02 1.8 2.93E-02 Metabolism
Cln3, ceroid lipofuscinosis, neuronal 3, juvenile NM_009907 1.7 4.55E-03 1.7 5.18E-03 Unknown
Arrb1, arrestin, beta 1 AK004614 1.7 6.77E-03 1.8 7.22E-03 Signal transduction
Cast, calpastatin AB026997 1.7 8.19E-03 1.8 2.99E-03 Metabolism
Nupr1, nuclear protein 1 NM_019738 1.7 4.92E-03 2.0 8.18E-03 Unknown
Jag2, jagged 2 AV264681 1.7 2.21E-02 1.6 1.15E-02 Signal transduction/Development/
Cell proliferation
Bckdha, branched chain ketoacid dehydrogenase
E1, alpha polypeptide
NM_007533 1.6 3.33E-02 1.8 1.30E-02 Metabolism/Transcription
Prkcn, protein kinase C, nu BF160591 1.6 1.17E-02 1.7 3.48E-03 Signal transduction
Pnp, purine-nucleoside phosphorylase AK008143 1.5 3.02E-03 1.5 2.90E-02 Metabolism
Tcf4, transcription factor 4 AI639846 1.5 2.96E-02 1.5 1.42E-02 Transcription/Development
doi:10.1371/journal.pone.0000768.t001
Table 1. cont.
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NUP98-HOX Fusion Target Genes
PLoS ONE | www.plosone.org 6 August 2007 | Issue 8 | e768nova AML samples collected at diagnosis from adult patients were
analyzed. Complete karyotype and FLT3-ITD status was known
for all subjects and represented FAB subclass M0-M5 morpho-
logically. Six patients had favorable, 19 had intermediate and 9
had unfavorable cytogenetics (Table 3). Quantitative real-time
RT-PCR with TaqManH Low density array (TLDA) was used to
measure gene expression, allowing analysis of all the selected genes
in several samples at the same time lowering assay variation and
increasing reproducibility. We tested a subset of Hox and Hox
cofactor genes, HOXA5, HOXA7, HOXA9, HOXA10, PBX1, PBX2,
PBX3, and MEIS1, and possible Hox target genes FLT3, HLF,
JAG2, MEF2C, DDX4, and PRNP. The gene expressions in
leukemia samples were normalized with the housekeeping gene
GUS as an endogenous control and the expression levels were
calculated relative to pooled normal bone marrow (Table 3).
Two of the selected genes could not be detected in the majority
of the samples in either normal or leukemia bone marrow
(HOXA10 and DDX4) and were therefore excluded from further
analysis. Analysis of the selected Hox A cluster and Hox cofactor
genes revealed a high degree of co-expression between these in
leukemia samples, where correlation coefficient between HOXA5,
HOXA7, HOXA9 and MEIS1 ranged between 0.83 and 0.92
(Spearman rank correlation, p,0.0001 in all cases, e.g. in
Figure 3A). PBX3 gene expression also correlated with these
(r=0.67–076, p,0.0001) but PBX2 and PBX1 did not. Further-
more, patients with intermediate or unfavorable cytogenetics had
significantly higher expression of MEIS1, PBX3, HOXA5, HOXA7
and HOXA9 compared to patients with favorable cytogenetics
(non-parametric Kruskal-Wallis ANOVA, e.g. HOXA7 p=0.0013
and p=0.018 respectively) but there was no significant difference
between patients with intermediate and unfavorable cytogenetics.
These findings suggest a tight co-regulation of these factors and
define a subset of homeodomain transcription factors linked to
leukemic development and are in concordance with other reports
[45,46].
Among the selected possible direct target genes, FLT3 gene
expression showed the closest association with HOXA5, HOXA7,
HOXA9 and MEIS1 (Spearman, r-value between 0.45–0.57,
p–value 0.016–0.0020) but no significant correlation was seen
with PBX3 expression (r=0.22, p=0.20). Furthermore, FLT3
expression showed a weak but significant correlation with bone
marrow blast counts (r=0.36, p=0.049). Moreover, FLT3
expression was significantly higher in patients with intermediate
or unfavorable cytogenetics (Kruskal-Wallis, p=0.047 and
Table 2. Validation of microarray results with quantitative
RT-PCR on unamplified RNA.
......................................................................
Gene
transcript
qRT-PCR
NA10
Array
NA10
qRT-PCR
ND13
Array
ND13
qRT-PCR
ND13
N51S
Array
ND13
N51S
Pbx1 1.7 1.1 2.6 1.3 0.9 1.1
Pbx2 0.9 1.3 1.1 1.1 0.6 1.0
Pbx3 5.4 5.0 4.2 4.9 0.4 0.8
HoxA5 7.5 3.2 7.7 2.1 1.7 0.9
HoxA7 1.7 2.1 3.0 2.8 0.5 0.2
HoxA9 2.4 1.6 2.9 1.2 0.8 1.0
HoxB4 2.9 2.5 1.5 1.4 0.8 1.1
Meis1 1.6 1.1 1.7 0.9 1.4 1.2
Flt3 5.8 2.2 10.1 2.3 2.1 1.1
Evi1 28.1 4.2 8.6 2.9 3.8 1.4
Anxa1 3.6 2.0 4.9 2.2 1.0 1.3
Tgfbi 2.2 1.8 5.6 2.2 1.7 1.1
c-Jun 1.1 1.5 5.3 3.4 1.1 3.4
Csf2rb 4.9 2.4 5.6 4.9 1.6 2.2
Ptprf 24.5 10.8 100.5 27.2 2.7 2.4
Fold changes are calculated against an empty MIG control and Gapdh as
endogenous control gene.
doi:10.1371/journal.pone.0000768.t002
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Cell adhesion, 3, 3%
Cell cycle, 5, 5%
Cell growth, 2, 2%
Cell proliferation, 6, 5%
Coagulation, 2, 2%
Development and 
differentiation, 16, 14%
Immune response, 4, 4%
Metabolism, 15, 14%
Signal transduction, 19, 
16%
Transcription, 16, 15%
Transport, 5, 5%
Unknown, 17, 15%
Figure 2. Annotation of differentially expressed genes. Genes that were differentially expressed by both ND13 and NA10 but not the mutant
ND13(N51S) mutant were classified according to involvement in different biological processes. Some genes are classified in more than one category
resulting in the total number of genes indicated in the figures being greater than the total number of differentially expressed genes.
doi:10.1371/journal.pone.0000768.g002
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PLoS ONE | www.plosone.org 8 August 2007 | Issue 8 | e768p=0.046 respectively) but there was no significant association
between FLT3 expression and FLT3-ITD status (p=0.74). Thus,
FLT3 expression was associated with HOXA5, HOXA7, HOXA9
and MEIS1 in human leukemia and this gene expression profile
was confined to leukemia with either intermediate or unfavorable
cytogenetics.
Expression of the HLF gene correlated significantly with HOXA7
and HOXA9 expression (Spearman, r=0.46, p=0.0060 and
r=0.43, p=0.011 respectively), but not with HOXA5 (r=0.24,
p=0.17), MEIS1 (r=0.25, p=0.15) or PBX3 (r=0.25, p=0.16).
The same association was seen for JAG2, with a positive correlation
with HOXA7 and HOXA9 gene expression (Spearman, r=0.46,
p=0.0062 and p=0.0068, respectively) but not with HOXA5,
MEIS1 or PBX3 (r=0.31, p=0.074, r=0.32, p=0.061 and
r=20.02, p=0.98 respectively). Furthermore, JAG2 and HLF gene
expression correlated (r=0.47, p=0.0052, Figure 3B) and there was
also a significant correlation between JAG2 and FLT3 expression
(r=0.39, p=0.024). Altogether, these findings suggest that HOXA7
and HOXA9 could be directly involved in JAG2 and HLF gene
regulation and possibly, unlike FLT3, independent of MEIS1.
The expression of the MEF2C and PRNP genes showed a tight
co-association (r=0.70, p,0.0001) and both showed significantly
higher expression in patients with unfavorable vs. favorable
cytogenetics (Kruskal-Wallis ANOVA, p=0.017 and p=0.026
respectively). However, their expression did not correlate with
HOXA5, HOXA7, HOXA9 or MEIS1 and only weakly with PBX3
expression in human leukemia (Spearman, r=0.37, p=0.033 and
r=0.44, p=0.078 respectively). This suggests that their induction
may be restricted to NUP98-Hox fusions and that they are not
regulated by the native HOXA5, HOXA7, HOXA9 or MEIS1 in
human bone marrow cells.
DISCUSSION
The goal of this study was to identify gene expression changes that
may underlie the potent growth promoting effects of Hox on
primitive hematopoietic cells. Our strategy included use of two
NUP98-Hox fusions with strong overlapping functional effects
versus a functionally ‘‘dead’’ mutant form coupled with analysis of
early induced gene expression changes in a HSC/progenitor cell
enriched fractions. Key results included the identification of
a limited number of induced genes mainly involved in cell
development, cell proliferation and signal transduction, consistent
with the potent effects of these fusions on promoting primitive
hematopoietic cell expansion and differentiation block in vitro and
their ability to collaborate in leukemic transformation [19,21,27].
Among the identified genes are several intriguing candidates as
HSC regulators and/or possible leukemogenic targets e.g. the
tyrosine receptor Flt3, the prion protein Prnp, the transcription
factor Hlf and the Notch ligand Jag2. Moreover, induction of
Hoxa5, Hoxa7, Hoxa9 and Pbx3 by ND13 and NA10 was observed
in HSC/progenitor cells that may define a minimal Hox
transforming profile that seems to be shared with other NUP98-
Hox and MLL fusions. Furthermore, FLT3, HLF and JAG2
expression correlated with Hox genes in human AML that both
confirms the fidelity of the microarray analysis and suggests the
importance of these genes for Hox genes ability to trigger HSC
expansion and to serve as a first step in leukemic transformation.
Importantly, several of the suggested target genes reported
herein overlap with those recently published by the study of
Chung et al., in which human CD34
+ cord blood was used to
investigate the effects induced by NUP98-HOXA9. These included
the HOXA5, HOXA7, HOXA9 and PBX3 genes but perhaps more
intriguing also HLF. Elevated HLF expression can both enhance
HSC engraftment and inhibit apoptosis [41]. The homeodomain
dependent induction of Hlf expression by ND13 and NA10 may
explain the proliferative advantage induced by these genes on
primary HSC and progenitor cells in vitro and the high level
expansion of long term repopulating cells induced NA10 [19,27].
The finding that HLF also correlated with HOXA7 and HOXA9 in
human leukemia suggests that this gene also might be important
for Hox induced cell transformation and development of leukemia.
The finding of homeodomain dependent induction of Jag2 by
ND13 and NA10 in Sca1
+, Lin
2 BM cells, and that JAG2
expression correlated with HOXA7 and HOXA9 expression in
AML samples is also very interesting since JAG2 was recently
found to be overexpressed in CD34(+)CD38(2) isolated leukemic
stem cells from AML patients [47]. Moreover, Serrate, the
Drosophila homologue of JAG2, has been identified as a compo-
nent of Hox-dependent pathways [48] and in C. elegans the Hox
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Figure 3. Correlation between HOXA7 and HOXA9 (A) and JAG2 and
HLF (B) gene expression in human AML analyzed with TaqMan Low
Density Array (TLDA). Spearman rank correlation analysis was done on
the log ratio values obtained from the TLDA assay and calculated with
the 2
2DDCT method (n=34).
doi:10.1371/journal.pone.0000768.g003
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LIN-12/Notch-mediated signaling and for the expression of the
genes encoding the LIN-12/Notch receptor and its ligand LAG-2/
Delta/Serrate [49]. Thus, the Notch signaling pathway might be
part of the effects induced by Hox and Hox co-factors.
Calvo et al. have reported that NUP98-HOXA9 enforce strong
transcription of endogenous Hoxa9 and Hoxa7, which further
strengthen that different NUP98-Hox fusions have common target
genes. HOXA9 is frequently induced in human AML with poor
prognosis [50] and Hoxa9 can induce leukemia in murine BM
transplantation models in collaboration with Meis1 [51] similar to
what we have shown for ND13 and NA10 [19,21]. Furthermore,
mixed-lineage-leukemia (MLL) fusion genes, induce a characteris-
tic pattern of Hox A cluster genes, including Hoxa7 and Hoxa9 in
myeloid cells [52]. Both these genes are required for efficient in
vitro myeloid immortalization by MLL-ENL and in a bone marrow
transplantation model Hoxa9 is essential for MLL-dependent
leukemogenesis in vivo [52]. Furthermore, deregulation of FLT3 or
FLT3 mutations are frequently found in AML [53]. Meis1 was
recently shown to directly induce Flt3 expression in murine BM
cells together with either Hoxa9 or ND13 or NA10 [43,44] and we
have also shown that high Flt3 expression is sufficient to induce
AML transformation in mice using preleukemic BM cells
expressing either ND13 or NA10 [43]. Interestingly, Flt3 has also
been reported to be expressed together with Pbx3, HoxA7, HoxA9
and Meis1 in a gene expression profile induced by MLL-ENL [54],
thus similar to what we observed for ND13 and NA10 in this
study. In addition, our results reveal an association between
HOXA5, HOXA7, HOXA9, MEIS1 and FLT3 expression in human
AML. In conclusion these findings indicate that induction of Flt3,
Hoxa7, Hoxa9 and Pbx3 and possibly other Hox genes (i.e. Hoxa5)
in part underlie the transforming effects of ND13 and NA10 and
perhaps support a common mechanism for leukemogenesis
triggered by both NUP98 and MLL fusion genes.
Finally, the gene array results also indicated that the NUP98-
Hox genes act principally as strong transcriptional activators.
Importantly, the set of genes that showed overlap between ND13
and NA10 were all induced genes suggesting that gene
transcription activation rather then repression is the key to their
functional effects on primitive hematopoietic cells. Interestingly, in
the study by Ghannam et al. where HOXA9 or NUP98-HOXA9
were expressed in myeloid cell lines, the majority of the genes
showed predominant induced expression [55]. Furthermore,
NUP98-HOXA9 affected about eight times more genes than
HOXA9, with a substantial number of them regulated by the
fusion but not by the native HOXA9 protein, intriguingly
including the Mef2c gene. The finding that the Mef2c gene was
induced also by both ND13 and NA10, but did not correlate with
Hox or Hox co-factor expression in human AML samples indicate
that this gene, plus the prion protein, Prnp, gene could be novel
direct targets of these NUP98-Hox fusions and not normally
effected by native HOXA5, HOXA7, HOXA9 or MEIS1 genes.
However, other Hox genes not included in our analysis could of
course still be involved in their regulation. In conclusion our
findings support that NUP98-Hox fusion proteins are aberrant
transcriptional activators whose activity depends on the DNA
binding homeodomain but also has stronger and wider transcrip-
tional effects than the native Hox protein. Findings by Chung et al.
provide evidence that this effect, at least in part, is mediated by
decreased susceptibility to CUL-4A-dependent ubiquitination of
NUP98-Hox fusions increasing their protein half-lives [56].
In summary this study identify gene expression changes that
involve several different biological processes important for HSC
self-renewal and proliferation and point to several interesting genes
suggesting that NUP98-Hox fusions target multiple mechanisms
that could potentially explain how they both transform and induce
expansion of HSCs, which in turn may lead to leukemia. The next
step in our investigation will be to elucidate their relative role in
these processes in animal models for HSC expansion and for
transforming activity. These results will also be of great help in
ongoing efforts for genome wide analysis of Hox binding sites and
for investigating direct binding of Hox and Hox co-factors to
regulator sequences.
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